KENYON LAWRENCE A Insider Trading Activity

Average Profitability
17.42%
Insider Buys Quantity
3
Insider Buys Sum
$69,126.00
Insider Sells Quantity
3
Insider Sells Sum
$72,530.10

Insider Activity of KENYON LAWRENCE A

According to the SEC Form 4 filings, KENYON LAWRENCE A, being in a position of

  1. Chief Financial Officer at Outlook Therapeutics, Inc.,
    оver the last 12 months, has bought 101010 shares for $100,000, and sold 0 shares,
    over all time since 2017-12-22, has bought 141010 shares for $169,126, and sold 65130 shares for $72,530.

Biography of KENYON LAWRENCE A

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $100,0001100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2026-08-14PurchaseOutlook Therapeutics, Inc.
OTLK
Chief Financial Officer
101,010
0.0707%
$0.99$100,000-17.61%
2024-09-26PurchaseOutlook Therapeutics, Inc.
OTLK
Chief Financial Officer
5,000
0.0216%
$5.69$28,446-68.75%
2021-04-20PurchaseOutlook Therapeutics, Inc.
OTLK
CEO, Pres, CFO, Treas & Secy
10,000
0.0061%
$1.83$18,300+17.42%
2019-09-18SaleOutlook Therapeutics, Inc.
OTLK
CEO, Pres, CFO, Treas & Secy
2,700
0.0095%
$1.70$4,590-35.5%
2019-02-07PurchaseOutlook Therapeutics, Inc.
OTLK
CEO, Pres, CFO, Treas & Secy
25,000
0.027%
$0.90$22,380-77.9%
2018-09-18SaleOutlook Therapeutics, Inc.
OTLK
CEO, Pres, CFO, Treas & Secy
10,100
0.0254%
$0.87$8,807-34.09%
2017-12-22SaleOutlook Therapeutics, Inc.
OTLK
CFO and Secretary
52,330
0.2004%
$1.13$59,133-22.88%
Total: 7
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.